Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
RATIONALE: Standard therapeutic approaches to reduce social anxiety in autistic adults have limited effectiveness. Since 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy shows promise as a treatment for other anxiety disorders, a blinded, placebo-controlled pilot study was conducted. OBJECTIVES: To explore feasibility and safety of MDMA-assisted psychotherapy for reduction of social fear and avoidance that are common in the autistic population. METHODS: Autistic adults with marked to very severe social anxiety were randomized to receive MDMA (75 to 125 mg, n = 8) or inactive placebo (0 mg, n = 4) during two 8-h psychotherapy sessions (experimental sessions) in a controlled clinical setting. Double-blinded experimental sessions were spaced approximately 1 month apart with 3 non-drug psychotherapy sessions following each. The primary outcome was change in Leibowitz Social Anxiety Scale (LSAS) Total scores from Baseline to one month after the second experimental session. Outcomes were measured again six months after the last experimental session. RESULTS: Improvement in LSAS scores from baseline to the primary endpoint was significantly greater for MDMA group compared to the placebo group (P = 0.037), and placebo-subtracted Cohen's d effect size was very large (d = 1.4, CI - 0.074, 2.874). Change in LSAS scores from baseline to 6-month follow-up showed similar positive results (P = 0.036), with a Cohen's d effect size of 1.1 (CI - 0.307, 2.527). Social anxiety remained the same or continued to improve slightly for most participants in the MDMA group after completing the active treatment phase. CONCLUSIONS: This pilot trial demonstrated rapid and durable improvement in social anxiety symptoms in autistic adults following MDMA-assisted psychotherapy. Initial safety and efficacy outcomes support expansion of research into larger samples to further investigate this novel treatment for social anxiety. TRIAL REGISTRATION: clinicaltrials.gov identifier, NCT02008396.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“MDMA has well documented prosocial effects in human subjects and a pilot study found that MDMA-assisted psychotherapy reduced social anxiety in ASD adults [178].”
From Neural circuits regulating prosocial behaviors (2023) · cites this paper as [178]
The cited source says what the claim attributes to it.
In the citing paper
“Entactogens and hallucinogens have shown promising results in preliminary clinical trials in disorders also characterized by social impairments such as depression, anxiety, post-traumatic stress disorder (PTSD), and autism spectrum disorders (ASD) (15–19).”
From Modulation of Social Cognition via Hallucinogens and “Entactogens” (2019) · cites this paper as [18]
In the citing paper
“it has been found to reduce social anxiety in adults with autism spectrum disorder (Danforth et al., 2018;Danforth, Struble, Yazar-Klosinski, & Grob, 2016).”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Danforth et al., 2018
In the citing paper
“MDMA-assisted psychotherapy has been shown to reduce social anxiety in autistic adults for up to 6 months after treatment (18).”
From Modulation of Social Cognition via Hallucinogens and “Entactogens” (2019) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
A Global Measure of Perceived Stress
Cohen, S., Kamarck, T., & Mermelstein, R. (1983) · Journal of Health and Social Behavior · doi:10.2307/2136404 · Cited by 32,807
Society and the Adolescent Self-Image
Rosenberg, M. (1965) · doi:10.1515/9781400876136 · Cited by 30,126
(1970) · Cited by 24,983
Gross, J. J., & John, O. P. (2003) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.85.2.348 · Cited by 11,929
Measuring individual differences in empathy: Evidence for a multidimensional approach.
Davis, M. H. (1983) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.44.1.113 · Cited by 10,272 · cited 1×
“In addition, change from baseline was assessed with secondary measures, including BDI-II, PSS, Interpersonal Reactivity Index (IRI) (Davis 1980; Davis 1983), Rosenberg Self-Esteem Scale (RSES) (Rosenberg 1965), STAI, Toronto Alexithymia Scale (TAS-20) (Bagby et al. 1994), The Awareness of Social…”
MethodComparison of Beck Depression Inventories -IA and -II in psychiatric outpatients
Beck, A. T., Steer, R. A., Ball, R., & Ranieri, W. F. (1996) · Journal of Personality Assessment · doi:10.1207/s15327752jpa6703_13 · Cited by 5,965
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
(1980) · Medical Entomology and Zoology · Cited by 4,712
The twenty-item Toronto Alexithymia scale—II. Convergent, discriminant, and concurrent validity
Bagby, R. M., Taylor, G. J., & Parker, J. D. A. (1994) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(94)90006-x · Cited by 2,427
A mechanism for impaired fear recognition after amygdala damage
Adolphs, R., Gosselin, F., Buchanan, T. W., Tranel, D., Schyns, P., & Damasio, A. R. (2005) · Nature · doi:10.1038/nature03086 · Cited by 1,331
Posner, K., Oquendo, M. A., Gould, M., Stanley, B., & Davies, M. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1035 · Cited by 1,025 · cited 7×
“2002), the Columbia Suicide Severity Rating Scale (C-SSRS) (Posner et al. 2011; Posner et al. 2007), LSAS (Liebowitz et al.”
MethodInfluentialMithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110378371 · Cited by 674
Social Phobia: Review of a Neglected Anxiety Disorder
Liebowitz, M. R. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790300097013 · Cited by 577
King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., Donnelly, C. L., Anagnostou, E., Dukes, K., Sullivan, L., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.30 · Cited by 482
GABA system dysfunction in autism and related disorders: From synapse to symptoms
Coghlan, S., Horder, J., Inkster, B., Mendez, M. A., Murphy, D. G., & Nutt, D. J. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.07.005 · Cited by 446
Human Pharmacology of MDMA: Pharmacokinetics, Metabolism, and Disposition
de la Torre, R., Farré, M., Roset, P. N., Pizarro, N., Abanades, S., Segura, M., Segura, J., & Camí, J. (2004) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200404000-00009 · Cited by 444
Mithoefer, M. C., Mithoefer, A. T., Feduccia, A. A., Jerome, L., Wagner, M., Wymer, J., Holland, J., Hamilton, S., Yazar-Klosinski, B., Emerson, A., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30135-4 · Cited by 439
Self-citationMackowiak, P. A. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03490120092034 · Cited by 419
Oehen, P., Traber, R., Widmer, V., & Schnyder, U. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112464827 · Cited by 400
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., Martin, S. F., Yazar-Klosinski, B., Michel, Y., Brewerton, T. D., & Doblin, R. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112456611 · Cited by 376
Self-citationBrain Serotonin and Dopamine Transporter Bindings in Adults With High-Functioning Autism
Nakamura, K., Sekine, Y., Ouchi, Y., Tsujii, M., Yoshikawa, E., Futatsubashi, M., Tsuchiya, K. J., Sugihara, G., Iwata, Y., Suzuki, K., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.137 · Cited by 352
McDonald, S., Bornhofen, C., Shum, D., Long, E., Saunders, C., & Neulinger, K. (2006) · Disability and Rehabilitation · doi:10.1080/09638280600646185 · Cited by 319
A. Bartz, J., & Hollander, E. (2006) · Hormones and Behavior · doi:10.1016/j.yhbeh.2006.06.018 · Cited by 311
Mindfulness-based therapy in adults with an autism spectrum disorder: a randomized controlled trial
Spek, A. A., van Ham, N. C., & Nyklíček, I. (2013) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2012.08.009 · Cited by 274
Uzunova, G., Pallanti, S., & Hollander, E. (2016) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2015.1085597 · Cited by 246
Dumont, G. J. H., Sweep, F. C. G. J., van der Steen, R., Hermsen, R., Donders, A. R. T., Touw, D. J., van Gerven, J. M. A., Buitelaar, J. K., & Verkes, R. J. (2009) · Social Neuroscience · doi:10.1080/17470910802649470 · Cited by 238
Effects of MDMA on sociability and neural response to social threat and social reward
Bedi, G., Phan, K. L., Angstadt, M., & de Wit, H. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1635-z · Cited by 206
McCallie, M. S., Blum, C. M., & Hood, C. J. (2006) · Journal of Human Behavior in the Social Environment · doi:10.1300/j137v13n03_04 · Cited by 204
Bastiaansen, J. A., Meffert, H., Hein, S., Huizinga, P., Ketelaars, C., Pijnenborg, M., Bartels, A., Minderaa, R., Keysers, C., & de Bildt, A. (2011) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-010-1157-x · Cited by 203
Linehan, M. M. (1993) · PsycEXTRA Dataset · doi:10.1037/e495912006-012 · Cited by 184
Carhart-Harris, R. L., Murphy, K., Leech, R., Erritzoe, D., Wall, M. B., Ferguson, B., Williams, L. T. J., Roseman, L., Brugger, S., De Meer, I., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.12.015 · Cited by 178
Grob, C. S., Poland, R. E., Chang, L., & Ernst, T. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00078-2 · Cited by 175
Self-citationKamilar-Britt, P., & Bedi, G. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.08.016 · Cited by 163
Gamma, A. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00130-5 · Cited by 162
Safety pharmacology of acute MDMA administration in healthy subjects
Vizeli, P., & Liechti, M. E. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117691569 · Cited by 145
MDMA enhances “mind reading” of positive emotions and impairs “mind reading” of negative emotions
Hysek, C. M., Domes, G., & Liechti, M. E. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2645-9 · Cited by 144 · cited 1×
“MDMA also promotes release of the neurohormone oxytocin (OT) (Dumont et al. 2009; Hysek et al. 2012; Kirkpatrick et al. 2014; Kuypers et al. 2017).”
BackgroundRoberts, A. L., Koenen, K. C., Lyall, K., Robinson, E. B., & Weisskopf, M. G. (2015) · Child Abuse & Neglect · doi:10.1016/j.chiabu.2015.04.010 · Cited by 134
Hysek, C. M., Simmler, L. D., Schillinger, N., Meyer, N., Schmid, Y., Donzelli, M., Grouzmann, E., & Liechti, M. E. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001132 · Cited by 126
Dolder, P. C., Müller, F., Schmid, Y., Borgwardt, S. J., & Liechti, M. E. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4650-5 · Cited by 117
Social anxiety in adult autism spectrum disorder
Bejerot, S., Eriksson, J. M., & Mörtberg, E. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.08.030 · Cited by 111
MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults
Danforth, A. L., Struble, C. M., Yazar-Klosinski, B., & Grob, C. S. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.03.011 · Cited by 110
Self-citationCarhart-Harris, R. L., Wall, M. B., Erritzoe, D., Kaelen, M., Ferguson, B., De Meer, I., Tanner, M., Bloomfield, M., Williams, T. M., Bolstridge, M., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001405 · Cited by 108
Plasma oxytocin concentrations following MDMA or intranasal oxytocin in humans
Kirkpatrick, M. G., Francis, S. M., Lee, R., de Wit, H., & Jacob, S. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.04.006 · Cited by 106
Kuypers, K. P., Dolder, P. C., Ramaekers, J. G., & Liechti, M. E. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117699617 · Cited by 89
An Open-Label Study of Levetiracetam for the Treatment of Social Anxiety Disorder
Simon, N. M., Worthington, J. J., Doyle, A., Hoge, E. A., Kinrys, G., Fischmann, D., Link, N., & Pollack, M. H. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0909 · Cited by 76
Hysek, C. M., & Liechti, M. E. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2761-6 · Cited by 70 · cited 1×
“MDMA is primarily a potent releaser of serotonin and norepinephrine, and to a lesser extent dopamine (de la Torre et al. 2004; Hysek and Liechti 2012).”
BackgroundVizeli, P., & Liechti, M. E. (2018) · PLOS ONE · doi:10.1371/journal.pone.0199384 · Cited by 36
Oxytocin receptor gene variation predicts subjective responses to MDMA
Bershad, A. K., Weafer, J. J., Kirkpatrick, M. G., Wardle, M. C., Miller, M. A., & de Wit, H. (2016) · Social Neuroscience · doi:10.1080/17470919.2016.1143026 · Cited by 35
Research works printed but not linked: 3
- Danforth A (2013) Courage, connection, clarity: a mixed-model, collective-case study of MDMA (ecstasy) experiences of autistic adults (doctoral dissertation). Retrieved from ProQuest Dissertations & Theses (PQDT) database. (UMI No. 3596826)
- First MB Spitzer RL Gibbon M Williams JB Structured clinical interview for DSM-IV-TR axis I disorders, research version, Patient edition 2002 New York New York Psychiatric Institute
- Kadel R, Kip KA (2012) SAS macro to compute effect size (Cohen’s d) and its confidence interval from raw survey data. In: Proceedings of the Annual Southeast SAS Users Group Conference
Cited by
De Gregorio, D., Aguilar-Valles, A., Preller, K. H., Heifets, B. D., Hibicke, M., Mitchell, J., & Gobbi, G. (2021) · The Journal of Neuroscience · doi:10.1523/jneurosci.1659-20.2020 · Cited by 259
“Recent data suggest that MDMA may also be efficacious in other clinical populations, including people with autism spectrum disorder (Danforth et al., 2018) and with alcohol use disorder (Sessa, 2018).”
Reviewing the Potential of Psychedelics for the Treatment of PTSD
Krediet, E., Bostoen, T., Breeksema, J., van Schagen, A., Passie, T., & Vermetten, E. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa018 · Cited by 260
“, 2019), and social anxiety in autistic adults (Danforth et al., 2018).”
BackgroundSartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
George, J. R., Michaels, T. I., Sevelius, J., & Williams, M. T. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.015 · Cited by 230
“…when used as an adjunct to therapy (Mithoefer et al., 2011, 2013) and is currently being investigated to treat social anxiety in adults with autism (Danforth et al., 2018; Danforth, Struble, Yazar-Klosinski, & Grob, 2016) as well as anxiety associated with terminal illness (Emerson et al.,…”
Method
Metadata
- Authors
- Danforth, A. L., Grob, C. S., Struble, C., Feduccia, A. A., Walker, N., Jerome, L., Yazar-Klosinski, B., & Emerson, A.
- Affiliations
- The Lundquist Institute (US)
- Harbor–UCLA Medical Center (US)
- California Institute of Integral Studies (US)
- Corresponding author
- Grob, Charles S.
- Venue
- Psychopharmacology
- Published
- 2018-09-08
- Volume
- 235
- Issue
- 11
- Pages
- 3137-3148
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- PMC
- PMC6208958
- OpenAlex
- W2892030583
- Semantic Scholar
- ecb0103428dfa0edeaf5e0169712661dab7eeca8
- Cited by
- 280
- References
- 50
- Citations by year
- 2026: 20 · 2025: 36 · 2024: 61 · 2023: 59 · 2022: 35 · 2021: 31 · 2020: 20 · 2019: 16
- FWCI
- 19.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- Psychopharmacology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Multidisciplinary Association for Psychedelic Studies (NA)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Social Sciences › Psychology › Social Psychology › Music Therapy and Health
- Keywords
- MDMA-assisted psychotherapy, social anxiety, autism spectrum disorder, autistic adults, treatment efficacy, treatment safety
- MeSH terms
- Adult, Anxiety, Autistic Disorder, Combined Modality Therapy, Double-Blind Method, Fear, Female, Humans, Male, Middle Aged, Pilot Projects, Psychotherapy, Treatment Outcome, Serotonin Agents, N-Methyl-3,4-methylenedioxyamphetamine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.